EUVIMEDScopri EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY 4.0

Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta‐analysis

Maximilian Meyer iD, Eriks Strazdins, Adrian Guessoum, Jean N Westenberg iD, Christian Appenzeller-Herzog, Marco E G V Cattaneo, R Michael Krausz, Kenneth M Dürsteler, Undine E Lang, Lars G Hemkens, Marc Vogel

Addiction · 2025-06 · 120 (6) · 1112-1126

DOI: 10.1111/add.70000 ↗

At a glance

Systematische Übersicht in Addiction, published online on 2025-02-09. Written by Maximilian Meyer and 10 co-authors. Institution: University Psychiatric Clinics Basel, University of Basel, Basel, Switzerland. Major MEDLINE topics: Analgesics, Opioid, Opioid-Related Disorders, Opiate Substitution Treatment. Cited 12 times so far (Crossref); 74 references. The full text is freely available (open access, CC BY 4.0). Funded by: Freiwillige Akademische Gesellschaft Basel (FAG), Freiwillige Akademische Gesellschaft.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and Aims Opioid agonist treatment (OAT) is established for opioid use disorder, but limited data on adverse effects exist. We aimed to review relative risks of adverse effects across opioid agonists.

Methods

Systematic review with pair‐wise meta‐analysis of randomized clinical trials. A search in Embase, Medline, PsycInfo, CENTRAL and the Web of Science Core Collection was performed from inception to 11 April 2024 (PROSPERO: CRD42022322722). Two reviewers independently extracted data and used the Cochrane Risk of Bias Assessment Tool. Certainty of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). Primary outcomes were constipation, sedation, pruritus, sweating, nausea and vomiting, headache and any non‐headache pain.

Results

We identified 25 eligible trials, including 4892 participants. Reported agonists were methadone, levomethadone, methadyl acetate, buprenorphine, buprenorphine/naloxone, slow‐release oral morphine (SROM), diacetylmorphine, hydromorphone and opium tincture. Buprenorphine (all formulations combined) was associated with a lower risk of sedation than methadone [risk ratio (RR) = 0.68 (95% confidence interval = 0.56–0.82)]; 1558 participants, 9 studies]. Methadone had a lower risk of sedation compared with SROM [RR = 0.63 (0.58–0.69); 356 participants, 2 studies] and a lower risk of nausea than methadyl acetate [RR = 0.56 (0.37–0.85); 913 participants, 3 studies]. There was high overall risk of bias in 92% of included trials due to limited and non‐systematic outcome assessment. Certainty of evidence was low or very low for all but one comparison with moderate certainty.

Conclusions

There is currently insufficient data to determine whether the rates of adverse effects differ across opioid agonist treatments for most outcomes, with several exceptions. Moreover, the certainty of evidence is currently low or very low due to a lack of rigorous outcome assessment.

Subjects

MeSH terms (MEDLINE)

Analgesics, OpioidOpioid-Related DisordersOpiate Substitution TreatmentHumansRandomized Controlled Trials as TopicMethadoneBuprenorphineMorphine

Author keywords

adverse eventsmedication for opioid use disorderopioid maintenancesafetyside effectssubstitution

Substances

Analgesics, OpioidMethadoneBuprenorphineMorphine

Authors and institutions

  • University Psychiatric Clinics Basel, University of Basel, Basel, Switzerland.
  • Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • School of Medicine, University College Cork, Cork, Ireland.
  • University Medical Library, University of Basel, Basel, Switzerland.
  • Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

ORCID profiles: Maximilian Meyer, Jean N Westenberg

Funding

  • Freiwillige Akademische Gesellschaft Basel (FAG)
  • Freiwillige Akademische Gesellschaft

Cite

APA

Meyer, M., Strazdins, E., Guessoum, A., Westenberg, J. N., Appenzeller-Herzog, C., Cattaneo, M. E. G. V., Krausz, R. M., Dürsteler, K. M., Lang, U. E., Hemkens, L. G., & Vogel, M. (2025). Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta‐analysis. Addiction, 120(6), 1112-1126. https://doi.org/10.1111/add.70000

Vancouver

Meyer M, Strazdins E, Guessoum A, Westenberg JN, Appenzeller-Herzog C, Cattaneo MEGV, et al. Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta‐analysis. Addiction. 2025;120(6):1112-1126. doi:10.1111/add.70000

BibTeX
@article{Meyer2025,
  author = {Meyer, Maximilian and Strazdins, Eriks and Guessoum, Adrian and Westenberg, Jean N and Appenzeller-Herzog, Christian and Cattaneo, Marco E G V and Krausz, R Michael and Dürsteler, Kenneth M and Lang, Undine E and Hemkens, Lars G and Vogel, Marc},
  title = {Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta‐analysis},
  journal = {Addiction},
  year = {2025},
  volume = {120},
  number = {6},
  pages = {1112--1126},
  doi = {10.1111/add.70000}
}
Start for free →